Using metabolomic analysis to understand inflammatory bowel diseases

Inflammatory Bowel Diseases

Volumn 17, Issue 4, 2011, Pages 1021-1029

  Lin, Hui Ming ^a,b,c   Helsby, Nuala A ^a   Rowan, Daryl D ^b,c   Ferguson, Lynnette R ^a,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED   (New Zealand)

^c Nutrigenomics New Zealand   (New Zealand)

Author keywords

Crohn's disease; Metabolite profiling; Metabolomic; Metabonomic; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; MERCAPTOPURINE;

CROHN DISEASE; DATA ANALYSIS; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; ENTERITIS; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IMMUNE DYSREGULATION; INTESTINE FLORA; MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

HUMANS; INFLAMMATORY BOWEL DISEASES; METABOLOMICS;

EID: 79952481100     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21426     Document Type: Review

References (87)

1. Lindon JC, Holmes E, Nicholson JK. Metabonomics techniques and applications to pharmaceutical research & development. Pharm Res. 2006;23:1075-1088. (Pubitemid 43946133)
2. Idle JR, Gonzalez FJ. Metabolomics. Cell Metab. 2007;6:348-351.
3. Oresic M. Metabolomics, a novel tool for studies of nutrition, metabolism and lipid dysfunction. Nutr Metab Cardiovasc Dis. 2009;19: 816-824.
4. Griffin JL. The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? Philos Trans R Soc Lond B Biol Sci. 2006;361:147-161.
5. Giovane A, Balestrieri A, Napoli C. New insights into cardiovascular and lipid metabolomics. J Cell Biochem. 2008;105:648-654.
6. Fiehn O. Combining genomics, metabolome analysis, and biochemical modelling to understand metabolic networks. Comp Funct Genomics. 2001;2:155-168. (Pubitemid 32590962)
7. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181-1189.
8. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369: 1641-1657. (Pubitemid 46722637)
9. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009;58:1152-1167.
10. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006;52:171-181. (Pubitemid 43185477)
11. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-431.
12. Florin TH, Paterson EW, Fowler EV, et al. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol. 2006;41:306-311.
13. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
14. Thia KT, Loftus EV Jr, Sandborn WJ, et al. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103:3167-3182.
15. Riordan AM, Ruxton CH, Hunter JO. A review of associations between Crohn's disease and consumption of sugars. Eur J Clin Nutr. 1998;52:229-238. (Pubitemid 28159617)
16. Shoda R, Matsueda K, Yamato S, et al. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr. 1996;63:741-745. (Pubitemid 26126594)
17. Amre DK, D'Souza S, Morgan K, et al. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. Am J Gastroenterol. 2007;102: 2016-2025. (Pubitemid 47301536)
18. Innis SM, Pinsk V, Jacobson K. Dietary lipids and intestinal inflammatory disease. J Pediatr. 2006;149:S89-96.
19. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998; 66:5224-5231. (Pubitemid 29044613)
20. Sokol H, Lay C, Seksik P, et al. Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis. 2008; 14:858-867.
21. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105:16731-16736.
22. Lupp C, Robertson ML, Wickham ME, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe. 2007;2:119-129. (Pubitemid 47209521)
23. Orholm M, Munkholm P, Langholz E, et al. Familial occurrence of inflammatory bowel disease. N Engl J Med. 1991;324:84-88.
24. Tysk C, Lindberg E, Jarnerot G, et al. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut. 1988; 29:990-996.
25. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40:955-962.
26. McGovern DP, Gardet A, Torkvist L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet. 2010;42:332-337.
27. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8:458-466. (Pubitemid 351733422)
28. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274. (Pubitemid 23320290)
29. Powrie F, Leach MW, Mauze S, et al. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol. 1993;5:1461-1471.
30. Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol. 2007;23:379-383. (Pubitemid 46878948)
31. Strober W, Murray PJ, Kitani A, et al. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol. 2006;6: 9-20. (Pubitemid 43279749)
32. Maeda S, Hsu LC, Liu H, et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science. 2005;307:734-738. (Pubitemid 40194645)
33. Noguchi E, Homma Y, Kang X, et al. A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol. 2009;10:471-479.
34. Marks D, Segal A. Innate immunity in inflammatory bowel disease: a disease hypothesis. J Pathol. 2007;214:260-266.
35. Himmel ME, Hardenberg G, Piccirillo CA, et al. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology. 2008;125:145-153.
36. Abraham C, Cho JH. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2008;60: 97-110.
37. Villas-Boas SG, Rasmussen S, Lane GA. Metabolomics or metabolite profiles? Trends Biotechnol. 2005;23:385-386.
38. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev. 2007;26:51-78. (Pubitemid 46051813)
39. Beckonert O, Keun HC, Ebbels TM, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc. 2007;2:2692-2703.
40. Dunn WB, Bailey NJ, Johnson HE. Measuring the metabolome: current analytical technologies. Analyst. 2005;130:606-625. (Pubitemid 40685888)
41. Tohge T, Fernie AR. Web-based resources for mass-spectrometry-based metabolomics: a user's guide. Phytochemistry. 2009;70:450-456.
42. Lenz EM, Wilson ID. Analytical strategies in metabonomics. J Proteome Res. 2007;6:443-458. (Pubitemid 46340149)
43. Serkova NJ, Glunde K. Metabolomics of cancer. Methods Mol Biol. 2009;520:273-295.
44. Pan Z, Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem. 2007;387:525-527. (Pubitemid 46067468)
45. Halket JM, Przyborowska A, Stein SE, et al. Deconvolution gas chromatography/ mass spectrometry of urinary organic acids - potential for pattern recognition and automated identification of metabolic disorders. Rapid Commun Mass Spectrom. 1999;13:279-284. (Pubitemid 29101096)
46. Smith CA, Want EJ, O'Maille G, et al. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem. 2006;78:779-787. (Pubitemid 43228585)
47. Izquierdo-Garcia JL, Rodriguez I, Kyriazis A, et al. A novel R-package graphic user interface for the analysis of metabonomic profiles. BMC Bioinformatics. 2009;10:363.
48. Katajamaa M, Oresic M. Processing methods for differential analysis of LC/MS profile data. BMC Bioinformatics. 2005;6:179.
49. van den Berg RA, Hoefsloot HC, Westerhuis JA, et al. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics. 2006;7:142.
50. Sangster T, Major H, Plumb R, et al. A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. Analyst. 2006;131:1075-1078. (Pubitemid 44465534)
51. Craig A, Cloarec O, Holmes E, et al. Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal Chem. 2006;78:2262-2267.
52. Dieterle F, Ross A, Schlotterbeck G, et al. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem. 2006;78:4281-4290.
53. Lindon JC, Nicholson JK. Analytical technologies for metabonomics and metabolomics, and multi-omic information recovery. TrAC Trends Anal Chem. 2008;27:194-204. (Pubitemid 351436617)
54. Eriksson L, Antti H, Gottfries J, et al. Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal Bioanal Chem. 2004;380:419-429.
55. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res. 2007;6:469-479. (Pubitemid 46340151)
56. Kuhara T. Diagnosis and monitoring of inborn errors of metabolism using urease-pretreatment of urine, isotope dilution, and gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;781:497-517. (Pubitemid 35351683)
57. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739-744.
58. Holmes E, Loo RL, Stamler J, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature. 2008;453:396-400. (Pubitemid 351693125)
59. Bictash M, Ebbels TM, Chan Q, et al. Opening up the "black box": metabolic phenotyping and metabolome-wide association studies in epidemiology. J Clin Epidemiol. 2010 [Epub ahead of print].
60. Williams HR, Cox IJ, Walker DG, et al. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol. 2009;104:1435-1444.
61. Marchesi JR, Holmes E, Khan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res. 2007;6:546-551. (Pubitemid 46340158)
62. Chen C, Shah YM, Morimura K, et al. Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab. 2008;7:135-147. (Pubitemid 351168558)
63. Lin HM, Barnett MP, Roy NC, et al. Metabolomic analysis identifies inflammatory and noninflammatory metabolic effects of genetic modification in a mouse model of Crohn's disease. J Proteome Res. 2010;9:1965-1975.
64. Lin HM, Edmunds SJ, Helsby NA, et al. Nontargeted urinary metabolite profiling of a mouse model of Crohn's disease. J Proteome Res. 2009;8:2045-2057.
65. Murdoch TB, Fu H, MacFarlane S, et al. Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-deficient mice. Anal Chem. 2008;80:5524-5531.
66. Sathish Kumar N, Eapen CE, Jeyamani R, et al. Serum and urinary fucose concentrations in hepatitis B-related cirrhosis and acute liver diseases. Clin Chim Acta. 2004;342:233-235. (Pubitemid 38352934)
67. Takahashi H, Saibara T, Iwamura S, et al. Serum alpha-L-fucosidase activity and tumor size in hepatocellular carcinoma. Hepatology. 1994;19:1414-1417.
68. Becker DJ, Lowe JB. Fucose: biosynthesis and biological function in mammals. Glycobiology. 2003;13:41R-53R.
69. Bliss SK, Bliss SP, Beiting DP, et al. IL-10 regulates movement of intestinally derived CD4+ T cells to the liver. J Immunol. 2007;178:7974-7983. (Pubitemid 46898068)
70. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol. 2006;6:244-251. (Pubitemid 43290993)
71. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic pro-files delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910-914.
72. Brindle JT, Antti H, Holmes E, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med. 2002;8:1439-1444. (Pubitemid 36019430)
73. Kirschenlohr HL, Griffin JL, Clarke SC, et al. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med. 2006;12:705-710. (Pubitemid 43865242)
74. Roussel R, Mentre F, Bouchemal N, et al. NMR-based prediction of cardiovascular risk in diabetes. Nat Med. 2007;13:399-400. (Pubitemid 46559813)
75. Achkar JP, Duerr R. The expanding universe of inflammatory bowel disease genetics. Curr Opin Gastroenterol. 2008;24:429-434.
76. Gieger C, Geistlinger L, Altmaier E, et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet. 2008;4:e1000282.
77. Illig T, Gieger C, Zhai G, et al. A genome-wide perspective of genetic variation in human metabolism. Nat Genet. 2010;42:137-141.
78. Bezabeh T, Somorjai RL, Smith IC. MR metabolomics of fecal extracts: applications in the study of bowel diseases. Magn Reson Chem. 2009;47(suppl 1):S54-61.
79. Bjerrum JT, Nielsen OH, Hao F, et al. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res. 2010;9:954-962.
80. Williams HR, Walker DG, North BV, et al. Letter: metabonomics in ulcerative colitis. J Proteome Res. 2010;9:2794-2795.
81. Derijks LJ, Wong DR. Pharmacogenetics of thiopurines in inflammatory bowel disease. Curr Pharm Des. 2010;16:145-154.
82. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005;20:1149-1157. (Pubitemid 41602556)
83. Clayton TA, Lindon JC, Cloarec O, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature. 2006;440:1073-1077.
84. Jansson J, Willing B, Lucio M, et al. Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS One. 2009;4:e6386.
85. Balasubramanian K, Kumar S, Singh RR, et al. Metabolism of the colonic mucosa in patients with inflammatory bowel diseases: an in vitro proton magnetic resonance spectroscopy study. Magn Reson Imaging. 2009;27:79-86.
86. Martin FP, Rezzi S, Philippe D, et al. Metabolic assessment of gradual development of moderate experimental colitis in IL-10 deficient mice. J Proteome Res. 2009;8:2376-2387.
87. Varma S, Bird R, Eskin M, et al. Detection of inflammatory bowel disease by proton magnetic resonance spectroscopy (1H MRS) using an animal model. J Inflamm (Lond). 2007;4:24.